MedTrace Logo

Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.

NCT05365386 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-12-03

Study results available
· View outcomes & findings →

Summary

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

Conditions

  • Actinic Keratoses

Interventions

DEVICE

Tixel C

This is a non-invasive thermo-mechanical treatment to the scalp and/or face using the Tixel technology.

Sponsors & Collaborators

  • Novoxel Ltd.

    lead INDUSTRY

Principal Investigators

  • Assi Levi, MD · Rabin Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-17
Primary Completion
2023-09-12
Completion
2023-09-12

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365386 on ClinicalTrials.gov